跳至主要内容
临床试验/ACTRN12606000154505
ACTRN12606000154505已完成1 期

A Phase I Single Dose Pharmacokinetic Study of DG17 versus DG17 in combination with Ritonavir in healthy subjects

arhex Life Sciences Ltd.0 个研究点目标入组 18 人开始时间: 2006年5月3日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 45 Years(—)
性别
Male

入选标准

  • Able to provide written informed consent· Able to comply with the requirements of the study· Able to provide a permanent residential address· Judged as healthy by medical history, physical examination and laboratory screening within 21 days of study entry· Test negative for HIV, hepatitis B and C· No evidence of drug or alcohol abuse· Willing to abstain from taking any prescription or over-the-counter medication while in the clinical trial – all health supplements were discontinued at least 7 days before the first treatment.

排除标准

  • Recent (within the last 12 months) of a serious medical illness or medical disorder· Subject currently taking prescription medications of any type, or non-prescription antacids (alkalis, H2 or proton pump inhibitors)· Current infection· Abnormal findings on physical examination· Abnormal screening laboratory values considered significant by the investigator· Donation of blood within the last 30 days· Participation in another clinical trial within the last 30 days· History of alcohol or drug abuse· Cigarette smokers.

研究者

发起方
arhex Life Sciences Ltd.

相似试验